Cleocin enhances the action of other neuromuscular blocking agents. Therefore, it should be used with caution in patients receiving such agents. Antagonism has been demonstrated between Cleocin and erythromycin in vitro. Because of possible clinical significance, these two drugs should not be administered concurrently.
Clindamycin is contraindicated in patients previously found to be sensitive to clindamycin or any of the ingredients of this medicine.
The adverse effects have been reported with the use of Cleocin are- abdominal pain, oesophagitis and oesophagial ulcer, nausea, vomiting and diarrhoea, pruritus, skin rashes, urticaria.
Pregnancy Category B. Clindamycin crosses the placenta in humans. After multiple doses, amniotic fluid concentrations were approximately 30% of maternal concentrations. Clindamycin should be used in pregnancy only if clearly needed. Clindamycin has been reported to appear in breast milk. Therefore, it is not recommended for nursing mothers if not clearly needed.
Overdosage with orally administered Cleocin has been rare. Adverse reactions similar to those seen with normal doses can be expected, however, unexpected reactions could occur. Haemodialysis and peritoneal dialysis are not effective in removing Cleocin from the serum. Overdosage should be treated with simple gastric lavage. No specific antidote is known.
Direction for reconstitution (powder for oral solution): Shake the bottle well to loosen the powder. Add 80 ml of boiled and cooled water to the dry mixture in the bottle. For ease of preparation, add water to the bottle in two proportions. Shake well after each addition until all the powder is in solution. Keep the bottle tightly closed. The reconstituted solution should be used within 2 weeks if kept at room temperature.
Dilution of Cleocin injection for intravenous use: Cleocin phosphate must be diluted prior to IV administration. The concentration of Cleocin in diluent for infusion should not exceed 18 mg per ml. Infusion rates should not exceed 30 mg per minute.
Administration of more than 1200 mg in a single 1 hour infusion is not recommended.
Single IM injections of greater than 600 mg are not recommended. Dilution is not required for intramuscular administration.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
